Press

2023-06-19

Kancera reports dosing of first patient in the KANDOVA study

Kancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.

Read More
2023-04-26

Kancera reports start of patient screening for the KANDOVA-study

Kancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.

Read More
2023-04-24

Kancera has submitted application to conduct First-In-Human study of KAND145

Kancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.

Read More
2022-12-22

Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology

Kancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology...

Read More
2022-10-27

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies

Kancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...

Read More
2022-10-20

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).

Read More
2022-09-27

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...

Read More
2022-09-22

Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer

Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...

Read More
2022-05-25

Kancera receives patent grant in US for the drug candidate KAND145

Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.

Read More
2021-12-06

Kancera appoints Peter Selin as Executive Vice President Corporate Development

Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.

Read More